ZEAL DC — Amylin Reset: LLY Sets the Bar, Street Polarized Between Threat and Validation (Nov 2025)
Context:
Lilly’s eloralintide Ph2 data (16–20% WL @48w) landed at the top end of expectations. Tolerability benign — vomiting < GLP-1s, psychiatric AEs ≈ placebo, fatigue the only standout. ZEAL dropped –11% on cross-read fears for petrelintide. The market now splits between “LLY just killed the trade” and “LLY just proved the class works.”
Lilly’s eloralintide Ph2 data (16–20% WL @48w) landed at the top end of expectations. Tolerability benign — vomiting < GLP-1s, psychiatric AEs ≈ placebo, fatigue the only standout. ZEAL dropped –11% on cross-read fears for petrelintide. The market now splits between “LLY just killed the trade” and “LLY just proved the class works.”
BNP Paribas Exane – Validation, Not Threat (Outperform, TP DKK 905, +90%)
Exane frames the LLY data as mechanistic validation rather than competitive damage.
Fatigue and headache rates at LLY leave scope for Petrelintide to differentiate on tolerability.
Maintains ~⅓ of DCF from Petrelintide; plays 2026 catalysts (Petrelintide Ph2 Q1, Survodutide Ph3 mid-year).
Fatigue and headache rates at LLY leave scope for Petrelintide to differentiate on tolerability.
Maintains ~⅓ of DCF from Petrelintide; plays 2026 catalysts (Petrelintide Ph2 Q1, Survodutide Ph3 mid-year).
Read-through: Buy-the-fear setup; safety optionality still under-owned.
Jefferies – “LLY Owns the Space Until Proven Otherwise” (Neutral)
Acknowledges amylin validation but argues Zealand is boxed-in.
LLY’s dose escalation works; its distribution, combo pipeline, and payer leverage give it portfolio gravity.
ZEAL must print optically superior data (~20 % WL, visibly cleaner AE profile) to regain relevance.
LLY’s dose escalation works; its distribution, combo pipeline, and payer leverage give it portfolio gravity.
ZEAL must print optically superior data (~20 % WL, visibly cleaner AE profile) to regain relevance.
Read-through: Dead money until data; LLY dominance defines the trade.
J.P. Morgan – Bar Raised, Read-Across Negative (Neutral)
Highlights eloralintide’s 16–20 % WL and tolerability on par with placebo.
Argues ZEAL’s dual amylin + calcitonin mechanism brings no clear benefit and possible extra GI risk.
Argues ZEAL’s dual amylin + calcitonin mechanism brings no clear benefit and possible extra GI risk.
Read-through: Benchmark raised; differentiation narrative undermined.
Goldman Sachs – “Risk Priced, Optionality Mispriced” (Buy, TP DKK 866, +104 %)
Calls the –11 % move an overreaction.
LLY’s data crystallise a known risk but confirm amylin validity.
Fatigue absent in Petrelintide Ph1, nausea milder, and gender skew makes data non-comparable.
Highlights 2026 catalyst stack (Petrelintide Ph2 + Survodutide Ph3) as a re-rating window.
LLY’s data crystallise a known risk but confirm amylin validity.
Fatigue absent in Petrelintide Ph1, nausea milder, and gender skew makes data non-comparable.
Highlights 2026 catalyst stack (Petrelintide Ph2 + Survodutide Ph3) as a re-rating window.
Read-through: Mechanism validated; ZEAL volatility mispriced; convex upside into 2026.
Barclays – “Bar Set High But Still Room for Petrelintide” (Overweight)
Notes eloralintide “sets the bar high” but sees space for Petrelintide to achieve 15–20 % WL with a clean safety profile.
Maintains Overweight rating; sees near-term volatility as noise.
Maintains Overweight rating; sees near-term volatility as noise.
Read-through: Balanced optimism — LLY leads, but ZEAL’s clean safety thesis keeps it relevant.
Investment Implications
- LLY defines the ceiling (~20 % WL, mild AEs) but validates the mechanism.
- BNP / GS / Barclays: constructive camp — mechanism proven, sell-off excessive, safety differentiation intact.
- Jefferies / JPM: defensive camp — LLY’s scale and data dominance cap ZEAL’s re-rating potential until 1H ’26.
- Core trade logic: Petrelintide Ph2 is now the single binary catalyst — confirm GLP-1-like efficacy without fatigue or GI drag, and ZEAL rerates 50 % +.
Desk line: LLY set the benchmark; GS and Barclays say that bar doesn’t erase the story — it defines the risk premium.
Sources: BNP Paribas Exane (6 Nov 25) · Jefferies (Comment Nov 25) · J.P. Morgan (Obesity Week 2025) · Goldman Sachs (7 Nov 25, Sharma et al.) · Barclays (Lisa Pham, Bloomberg 7 Nov 25).